Adipocyte fatty-acid-binding protein, aP2 (FABP4) is expressed in adipocytes and macrophages, and integrates inflammatory and metabolic responses. Studies in aP2-deficient mice have shown that this lipid chaperone has a significant role in several aspects of metabolic syndrome, including type 2 diabetes and atherosclerosis. Here we demonstrate that an orally active small-molecule inhibitor of aP2 is an effective therapeutic agent against severe atherosclerosis and type 2 diabetes in mouse models. In macrophage and adipocyte cell lines with or without aP2, we also show the target specificity of this chemical intervention and its mechanisms of action on metabolic and inflammatory pathways. Our findings demonstrate that targeting aP2 with small-molecule inhibitors is possible and can lead to a new class of powerful therapeutic agents to prevent and treat metabolic diseases such as type 2 diabetes and atherosclerosis.
Lipids and lipid signals are critical in the integration of metabolic and inflammatory response systems and consequently play significant parts in the pathogenesis of a cluster of chronic metabolic diseases, including type 2 diabetes, fatty liver disease and atherosclerosis 1 . However, how lipids couple to target signalling pathways or metabolic processes and how their intracellular trafficking is regulated are poorly understood. Cytoplasmic fatty-acid-binding proteins (FABPs) are a family of 14-15-kDa proteins that bind with high affinity to hydrophobic ligands such as saturated and unsaturated long-chain fatty acids and eicosanoids such as hydroxyeicosatetraenoic acid, leukotrienes and prostaglandins 2 . The adipocyte FABP, aP2 (FABP4), is highly expressed in adipocytes and regulated by peroxisome-proliferator-activated receptor-c (PPARc) agonists, insulin and fatty acids [2] [3] [4] [5] . Studies in aP2-deficient mice have shown that aP2 has a significant role in many aspects of metabolic syndrome. Deficiency of aP2 partially protects mice against the development of insulin resistance associated with genetic or diet-induced obesity 6, 7 . Adipocytes of aP2 2/2 mice have reduced efficiency of lipid transport in vitro and in vivo, and yet exhibit only minor changes in serum lipids 8 . Interestingly, recent studies demonstrated that aP2 is also expressed in macrophages and regulated by phorbol 12-myristate 13-acetate, lipopolysaccharide, oxidized low-density lipoproteins and PPARc ligands [9] [10] [11] [12] . The macrophage is a critical site of FABP action, and total or macrophage-specific aP2-deficiency leads to a marked protection against early and advanced atherosclerosis in apolipoprotein E-deficient (Apoe 2/2 ) mice 9, 13 . These findings indicate an important role for aP2 in the development of major components of metabolic syndrome through its distinct actions in adipocytes and macrophages of integrating metabolic and inflammatory responses. Hence, pharmacological agents that modify FABP function may offer therapeutic opportunities for many components of metabolic syndrome, such as insulin resistance, type 2 diabetes, and atherosclerosis. Here, we demonstrate the first evidence of the efficacy of a novel chemical aP2 inhibitor in experimental models.
Inhibition of aP2 in cellular models BMS309403 (Fig. 1a) is a rationally designed, potent, and selective inhibitor of aP2 that interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. In a fluorescent 1,8-anilino-8-naphthalene sulphonate (ANS) binding displacement assay, BMS309403 exhibited K i values ,2 nM for both mouse and human aP2, compared with 250 nM for muscle FABP (FABP3) and 350 nM for mal1 (FABP5) 14 . In this assay, the endogenous fatty acids palmitic acid and oleic acid exhibited aP2 K i values of 336 and 185 nM, respectively. Results of X-ray crystallography studies suggested the specific interactions of BMS309403 with key residues in the fattyacid-binding pocket are the basis of its high in vitro binding affinity and selectivity for aP2 over other FABPs 14 . To test the specificity of aP2 inhibition by BMS309403, we developed and used a cellular system with aP2 1/1 and aP2
2/2 macrophage cell lines 9, 15 . In addition, we reconstituted aP2 expression in the aP2 2/2 cells (aP2 2/2 R). As shown in Fig. 1b , aP2 protein was expressed in the THP-1 (a human monocytic leukaemia cell line), aP2 1/1 , and aP2 2/2 R macrophages but was not detected in the aP2 2/2 macrophages. In all of the cell lines, mal1 was present (Fig. 1b, c) . Similarly, aP2 messenger RNA was readily detectable in THP-1, aP2
1/1 and aP2 2/2 R but not in the aP2 2/2 macrophages (Fig. 1c) . In this system, we examined the impact of aP2 inhibition on production of monocyte chemoattractant protein (MCP)-1 (also known as CCL2), an important aP2-regulated atherogenic product 9, 15 , in macrophages. Treatment with BMS309403 significantly decreased MCP-1 production from THP-1 macrophages in a dose-and time-dependent manner (Fig. 1d, Supplementary Fig. 1 ). To address whether this effect is specific, we next investigated MCP-1 production using
R mouse macrophage cell lines. In a similar way to THP-1 cells, production of MCP-1 from macrophages was decreased in aP2 1/1 cells in a dose-dependent fashion. In contrast, BMS309403 had no effect on MCP-1 production in aP2 2/2 cells at any dose tested. However, re-expression of aP2 (aP2 2/2 R) rendered the aP2 2/2 cells responsive to BMS309403 treatment, resulting in a dose-dependent reduction in MCP-1 production and demonstrating the target specificity of this compound (Fig. 1e) .
The impact of aP2 inhibition on atherosclerosis To address whether inhibition of aP2 can alter the development of vascular lesions, we performed early and late intervention studies in the Apoe 2/2 mouse model of atherosclerosis on a western diet. In the early intervention study, a western diet and the aP2 inhibitor BMS309403 were started simultaneously in 5-week-old mice (Supplementary Fig. 2a ). In the late intervention paradigm, the aP2 inhibitor was administered after 8 weeks of a western diet (at 12 weeks of age), when significant atherosclerosis has developed (Fig. 2a) . Analysis of the en face aorta demonstrated marked reductions in atherosclerotic lesion area in the aP2-inhibitor-treated group compared with the vehicle group in both the early (52.6%, Supplementary Fig. 2a, b) and late (51.0%, Fig. 2a, b ) intervention studies. Staining of cross-sections of the proximal aorta with Oil Red O revealed fatty streak lesions ( Fig. 2c and Supplementary Fig. 2c ). These were almost exclusively macrophage-derived foam cells, as determined by immunohistochemical staining with MOMA-2 ( Fig. 2d and Supplementary Fig. 2d ). Macrophages were located predominantly on the luminal surface of the lesions. The extent of atherosclerotic lesion area in the proximal aorta was significantly reduced in the aP2-inhibitor-treated group compared with vehicletreated controls in both the early (Supplementary Fig. 2e ) and late ( Fig. 2e ) intervention studies.
The aP2 inhibitor did not influence body weight, systemic glucose or lipid metabolism in Apoe 2/2 mice (Supplementary Table 1 ). Examination of the distribution of cholesterol among the serum lipoprotein fractions by size-exclusion chromatography revealed similar lipoprotein profiles between the groups with a large peak in the very low density lipoprotein fractions and a reduced high density lipoprotein peak that was due to APOE-deficiency in both the early (Supplementary Fig. 2f ) and late (Fig. 2f) intervention studies. No significant difference in glucose levels during glucose tolerance tests was observed between the vehicle and aP2 inhibitor groups (Supplementary Fig. 3a, b) . These results are consistent with previous observations made in mice with genetic deficiency of aP2 in the Apoe 2/2 background 9, 13 .
Cholesterol and inflammatory responses in macrophages Macrophage foam cell formation has a critical role in the pathogenesis of atherosclerosis and is a process regulated by FABPs 9 . Transformation of THP-1 macrophage to foam cells was significantly reduced in the presence of aP2 inhibitor (25 mM) (Fig. 3a) . The aP2-inhibitor-treated THP-1 macrophages exhibited 44% reduction in cholesterol ester accumulation compared with vehicle-treated macrophages (Fig. 3b) . In aP2 1/1 and aP2 2/2 R macrophages treated with the aP2 inhibitor, total cellular cholesterol ester content was significantly lower than in macrophages treated with vehicle ( Fig.  3c) . The aP2 inhibitor did not affect cholesterol ester content in the aP2 2/2 macrophages, again demonstrating the specificity of aP2 inhibitor action in this context.
To determine the potential mechanism for the reduction in cholesterol ester accumulation on inhibition of aP2, we examined APOA1-mediated cholesterol efflux in these cells. Cholesterol efflux from human THP-1 macrophages was significantly increased on treatment with the aP2 inhibitor (Fig. 3d ). There was a significant increase in both mRNA and protein levels of the ATP-binding cassette A1 (ABCA1) protein, a critical mediator of cholesterol efflux in macrophages, in the aP2-inhibitor-treated THP-1 cells compared with vehicle-treated controls ( Supplementary Fig. 4a, b) . Consistent with earlier observations 15 , cholesterol efflux in aP2 2/2 macrophages was substantially higher than that of the aP2 1/1 cells ( Fig. 3e ) and was completely abrogated with reconstitution of aP2 expression. Similar to genetic deficiency, treatment with the aP2 inhibitor significantly increased cholesterol efflux in the aP2 1/1 and aP2 2/2 R macrophages but not in the aP2 2/2 cells. We also examined the impact of aP2 inhibition on principal target molecules that regulate cellular cholesterol ester synthesis and hydrolysis in macrophages.
There was a modest reduction in acyl-coenzyme A: cholesterol-acyltransferase 1 (ACAT1), a key enzyme of cholesterol esterification, in the aP2-expressing macrophages (Fig. 3f ) but no effect of aP2 inhibition on the expression of hormone-sensitive lipase, which acts as the neutral cholesterol esterase, in macrophages ( Supplementary Fig. 5 ).
Macrophages participate in the pathogenesis of atherosclerosis not only through the formation of foam cells but also by the production of inflammatory mediators. Hence, we determined the impact of aP2 inhibition on several critical chemoattractant and inflammatory cytokines, including MCP-1, interleukin (IL)1b, IL6 and tumour necrosis factor (TNF) in macrophages. Expression of these cytokines was significantly reduced in the aP2-expressing macrophages treated with the aP2 inhibitor compared with those treated with vehicle ( Fig. 3g-j) . No regulation was evident in aP2 2/2 cells on treatment with the inhibitor, demonstrating the target specificity of the aP2 inhibitor.
Inhibition of aP2 in adipocytes
The main site of aP2 expression is the adipocyte and although this site does not play a major part in atherosclerosis, it does significantly Tnf/18s(AU) ARTICLES contribute to systemic insulin resistance and type 2 diabetes 6, 7, 9 . To begin to address the specific action of aP2 inhibition in adipocytes, we generated wild-type (aP2
) pre-adipocyte cell lines as well as FABP-deficient cells reconstituted with exogenous aP2 or with control empty vector. These cell lines fully differentiate into adipocytes and in all properties tested, behave in a similar way to commonly used 3T3-L1 or 3T3-F442A adipocytes (Fig. 4a) . In genetic aP2-deficiency, the principal alteration observed in adipocytes thus far is a reduction in fatty acid transport 8 . Hence, we asked whether the chemical inhibition of aP2 could mimic this action in adipocytes and do so in an aP2-dependent fashion. Treatment with the aP2 inhibitor resulted in a dose-dependent decrease in fatty acid uptake in wild-type adipocytes (Fig. 4b) . In contrast, there was no action of this inhibitor at any dose in FABP-deficient adipocytes. However, when aP2-deficient cells were reconstituted with aP2, they were rendered responsive to aP2 inhibition in a dose-dependent manner. Hence, the action of the synthetic aP2 inhibitor of regulating lipid transport in adipocytes was specific to its target, aP2.
Inhibition of aP2 in obese and diabetic mice Having established the target specificity of BMS309403 in adipocytes, we administered the compound into a genetic model of obesity and insulin resistance, the leptin-deficient ob/ob (also known as Lep ob/ob ) mouse, and investigated insulin sensitivity and glucose metabolism. During the course of the 6-week treatment, there was no significant difference in body weight between animals receiving vehicle or aP2 inhibitor ( Supplementary Fig. 6a) . Similarly, per cent body fat, rates of oxygen consumption and carbon dioxide production, food intake, and physical activity were not different between the vehicle and aP2 inhibitor treatment groups ( Supplementary Fig. 6b-f) . In contrast, blood glucose levels in both the fed and fasted state were decreased after treatment with the aP2 inhibitor (Fig. 4c) . Similar to genetic aP2-deficiency on the ob/ob background 7 , free fatty acid levels showed a trend towards an increase after treatment with the aP2 inhibitor (Supplementary Table 2 , P 5 0.07). The aP2 inhibitor decreased insulin and triglyceride levels and increased adiponectin concentration (Fig. 4d , e, and Supplementary Table 2), suggesting a potential increase in systemic insulin sensitivity. In fact, glucose tolerance tests revealed a significant improvement in glucose metabolism in the aP2-inhibitor-treated group (Fig. 4f) . Similarly, insulin tolerance tests showed significantly increased insulin sensitivity in the ob/ob mice treated with the aP2 inhibitor (Fig. 4g) . At the end of the treatment period, we analysed islet morphology in the pancreas. There was no difference in the pancreatic morphology such as the size, shape, and organization of the non-b-cell mantle between the vehicle-and aP2-inhibitor-treated ob/ob mice ( Supplementary Fig. 7) .
We also investigated the effect of aP2 inhibition in a diet-induced obesity model using both wild-type and FABP-deficient mice. The aP2-inhibitor-treated wild-type mice showed a significant decrease in glucose levels during glucose tolerance tests compared with vehicle-treated animals, but there was no change in glucose levels between the vehicle-and aP2-inhibitor-treated FABP-deficient mice on a high-fat diet (Supplementary Fig. 8 ). These results demonstrate that the insulin-sensitizing effects of the aP2 inhibitor in vivo are target-specific and effective in two independent models of obesity and insulin resistance.
Furthermore, we performed hyperinsulinaemic-euglycaemic clamp studies in ob/ob mice after 4 weeks of treatment. There was no significant difference in basal hepatic glucose production between the vehicle and aP2-inhibitor groups, but clamp hepatic glucose production was significantly suppressed in the aP2-inhibitor-treated ob/ob mice compared with vehicle-treated controls (Fig. 4h) . Both whole-body glucose disposal and glucose infusion rates were also significantly increased after treatment with the aP2 inhibitor (Fig.  4i ). These data demonstrate that the aP2 inhibitor improves wholebody insulin sensitivity through the suppression of hepatic glucose production and enhancement of insulin-stimulated glucose disposal in peripheral tissues. To explore this further, we determined the rate of glucose uptake in gastrocnemius muscle and epididymal fat during the clamp procedure. In the aP2-inhibitor-treated mice, glucose uptake in muscle and adipose tissues was significantly increased compared with that in the vehicle-treated controls (Fig. 4j) .
Effects of aP2 inhibition on adipose tissue in ob/ob mice Adipocyte size in ob/ob mice treated with the vehicle or aP2 inhibitor was comparable, but macrophage infiltration in adipose tissue was more severe in the vehicle-treated group (Fig. 5a) . Expression of two macrophage markers, F4/80 (Emr1) and Cd68, was significantly 1 aP2) , and FABP-deficient with vector (KO 1 GFP) adipocyte cell lines. b, Fatty acid uptake using 3 Hstearate in adipocyte cell lines. c, Blood glucose levels in ob/ob mice treated with vehicle (n 5 6) or aP2 inhibitor (n 5 6) at the fed state after 2 weeks of treatment and at the fasting state after 6 weeks of treatment. d, e, Plasma levels of insulin (d) and adiponectin (e) in ob/ob mice treated with vehicle (n 5 6) or aP2 inhibitor (n 5 6) for 6 weeks. f, Glucose tolerance tests performed after 4 weeks of treatment in ob/ob mice with vehicle (open circle, n 5 6) or aP2 inhibitor (closed circle, n 5 6). g, Insulin tolerance tests performed after 5 weeks of treatment in ob/ob mice with vehicle (open circle, n 5 6) or aP2 inhibitor (closed circle, n 5 6). h-j, Hyperinsulinaemic-euglycaemic clamp studies performed in ob/ob mice treated with vehicle (n 5 7) or aP2 inhibitor (n 5 9) for 4 weeks. Basal and clamp hepatic glucose production (HGP) (h), glucose disposal rate (Rd) and glucose infusion rate (GIR) (i), and tissue glucose uptake in gastrocnemius muscle and epididymal fat (j). Data are shown as the mean 6 s.e.m. *P , 0.05, **P , 0.01. reduced in the aP2-inhibitor-treated mice compared with vehicletreated controls (Fig. 5b, c) . Obesity leads to increased production of several chemoattractant and inflammatory cytokines, which have a critical role in obesity-associated inflammation and metabolic pathologies. Expression of Mcp-1, Il1b, Il6 and Tnf in adipose tissue was significantly reduced in ob/ob mice treated with the aP2 inhibitor compared with those treated with the vehicle (Fig. 5d-g ).
Obesity-induced Jun N-terminal kinase (JNK) 1 activity is critical in the generation of inflammatory responses and inhibition of insulin action 16, 17 . To examine whether aP2 inhibition modifies the inflammatory profile and insulin action by this mechanism, we determined JNK1 activity in the adipose tissue of vehicle-and aP2-inhibitor-treated ob/ob mice. There was a significant attenuation (40%) of obesity-induced adipose tissue JNK1 activity in mice treated with aP2 inhibitor compared with vehicle-treated controls (Fig. 5h) .
We next examined whether inhibition of aP2 and the alterations seen in inflammatory mediators and JNK activity in adipose tissue resulted in enhanced insulin action at this site. Insulin receptor signalling capacity was examined biochemically in intact mice following insulin administration. Insulin-stimulated tyrosine 1162/1163 phosphorylation of insulin receptor b subunit (IRb or INSRb subunit) and serine 473 phosphorylation of AKT were significantly increased in the adipose tissue of aP2-inhibitor-treated ob/ob mice compared with that of vehicle-treated controls (Fig. 5i) . These results demonstrate that aP2 inhibition reduced inflammation and increased insulin sensitivity in the adipose tissues of ob/ob mice.
Effects of aP2 inhibition on liver in ob/ob mice In genetic aP2-deficiency, there is a striking molecular compensation through increased expression of mal1 in adipose tissue 6 . Owing to this compensation, the phenotype of aP2-deficiency is much milder than aP2-mal1 combined deficiency 18 . We show here that the compensatory increase in mal1 expression of adipose tissue in the genetic absence of aP2 also occurs in the ob/ob background (Fig. 6a) . Because the aP2-inhibitor-treated animals exhibit a significant protection against metabolic disease, we asked whether the compensatory increase in mal1 expression was present or not under these circumstances. Interestingly, after 6 weeks of the aP2-inhibitor treatment, there was no change in levels of aP2 or mal1 protein in the adipose tissue (Fig. 6a) . This is a critical observation contributing to the efficacy of chemical inhibition of aP2 action in adult animals. For example, in genetic aP2-deficiency, there is no protection against fatty liver disease but a profound protection is seen in aP2-mal1 combined deficiency 18, 19 . In the aP2-inhibitor-treated ob/ob mice, fatty infiltration of the liver was attenuated (Fig. 6b) with a significant reduction in total liver triglyceride content (Fig. 6c) . This reduction in fatty liver disease on aP2 inhibition was associated with diminished expression of key lipogenic enzymes in liver, including the stearoyl-CoA desaturase 1 (Scd1), fatty acid synthase (Fasn), and acetyl-CoA carboxylase 1 (Acaca) (Fig. 6d-f ). This phenotype is reminiscent of aP2-mal1 combined deficiency rather than isolated aP2-deficiency 18, 19 . In a similar way to adipose tissue, total JNK1 activity in the liver tissue of aP2-inhibitor-treated ob/ob mice was significantly reduced (43%) compared with that of vehicle-treated control mice (Fig. 6g) . Suppression of fatty liver infiltration and inflammatory responses in aP2-inhibitor-treated ob/ob mice also resulted in enhanced insulin action in the liver. Insulin-stimulated tyrosine 1162/1163 phosphorylation of IRb and serine 473 phosphorylation of AKT were significantly increased in the liver tissue of aP2-inhibitor-treated ob/ob mice compared with vehicle-treated controls (Fig. 6h) .
Discussion
A principal mechanistic core of obesity, type 2 diabetes and atherosclerosis resides at the interface of metabolic and inflammatory pathways 1 . However, this mechanistic platform has not yet been exploited for the development of effective therapeutic strategies. 
ARTICLES
The locus for the adipocyte/macrophage FABP aP2 is critical in the regulation and dysregulation of metabolic and inflammatory responses as they relate to metabolic diseases [6] [7] [8] [9] 13, 15 . In addition to cell-autonomous effects in macrophages and adipocytes, aP2 also acts to coordinate the functional interactions between these two critical cell types in adipose tissue. Genetic deletion of the aP2 gene in mice has demonstrated a strong role for this molecule in several chronic metabolic diseases, most notably, atherosclerosis and type 2 diabetes, and has raised the possibility of using aP2 as a potential drug target. Here, we have provided a critical proof of principle in mice that aP2 could be successfully targeted by an orally active, smallmolecule inhibitor to generate a profile reminiscent of genetic deficiency in vitro and in vivo.
There are several indications that FABPs might be involved in metabolic homeostasis in a similar fashion in humans. First, the expression and regulation patterns of aP2 are very similar in both adipocytes and macrophages between mice and humans 2, 6, 9 . Expression of aP2 is highly regulated on macrophage activation and, interestingly, suppressed by a statin in vitro 20 . In both mouse and human macrophages, aP2 expression modulates inflammatory responses, foam cell formation and cholesterol efflux 9, 15 . Atherosclerotic lesions express high levels of aP2 in both mice and humans 9, 13, 21 . Finally, aP2 expression is increased in obesity 22 . Hence, it is possible that aP2 function may be similar in humans as well. In fact, in a recent study, we produced genetic support for this concept in humans 23 . A rare genetic variant was identified at the promoter region of the human aP2 orthologue FABP4, coinciding with the binding site for C/EBP. This particular mutation alters C/EBP binding and significantly reduces the transcriptional activity of the human aP2 promoter and the expression level of aP2 in the tissues of the carriers. In a large population sampling, individuals with the aP2 variant had lower triglyceride levels, exhibited reduced cardiovascular disease risk and were protected from obesity-induced type 2 diabetes. This study offers a critical insight and indicates that the metabolic function of aP2 in humans may be similar to that observed in mouse models. It is therefore possible that chemical inhibition of aP2 in humans might also show beneficial effects against diabetes and cardiovascular disease.
METHODS SUMMARY
The synthetic agent BMS309403 is a selective, high-affinity inhibitor of aP2. Information on synthesis and chemical properties has recently been reported 14 . Human monocytic leukaemia THP-1 cells were obtained from ATCC. Immortalized aP2 1/1 and aP2 2/2 mouse macrophage cell lines were generated in our laboratory as described 9, 15 . Wild-type (aP2
2/2 ) pre-adipocytes were developed using a previously described protocol 24 . The FABP-deficient pre-adipocytes were reconstituted by lentivirus with exogenous aP2 or with control empty vector including green fluorescent protein. All Apoe 2/2 and ob/ob mice were from Jackson Laboratory, and aP2 2/2 mal1 2/2 mice were generated as previously described 18 . All mice have the C57BL/6J genetic background. The aP2 inhibitor was administered by oral gavage. Quantification of atherosclerotic lesions was performed as previously described 25 . Hyperinsulinaemic-euglycaemic clamps were performed by modification of a described procedure 26 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
